HK/China Equity Long-Short

Osbert Tang, CFA

Osbert Tang is an equity analyst with over 20 years of experience with focuses on China transport, infrastructure, industrials and utilities sectors. He has been based in Shanghai since 2003, accumulated nearly 20 years of on-ground knowledge on the Chinese economy and financial markets, and has a wealth of contacts with China corporates and government entities. 

Osbert has received votes from top-tier institutional investors and has been a highly-ranked transport and infrastructure analyst in the Asiamoney, Institutional Investors and Greenwich surveys. In addition to his extensive experience with international investment banks including RBS, ABN AMRO (both served as Shanghai Chief Representative), Paribas Asia Equity, Maybank Kim Eng and DBS Securities, he has been a senior analyst with Moody’s Investors Service with focus on ratings of China infrastructure and related LGFV issuers. He has also worked in the area of strategic development at Sun Hung Kai Properties Limited. 

Osbert holds a BBA from the Chinese University of Hong Kong, an MBA from the University of Texas at Austin and a MSSc in Applied Psychology from the City University of Hong Kong. He was accredited with the CFA charter in 1997, and is a member of both British Psychological Society and Hong Kong Psychological Society.

China Strategy: 1H25 Roundup and Implications for 2H25

China Strategy: Interesting H-Share Securities Companies

China & HK Strategy: The High-Yield Playbook

CICC (3908 HK): It Is the Best of the Time

HK Strategy: How to Play the Future H IPOs of the As

China Strategy: Interesting Stock Picks for 2H25

China Heavy Machinery Sector: Anticipating More Upside

Thematic (Sector/Industry)

China Financials / Thematic (Sector/Industry)

<ul>
<li>The A-H share premium has narrowed by an average of 35pp YTD. Despite the recent A-share recovery, the premium remains depressed relative to the start of the year.</li>
<li>Aggressive players may keep playing the leaders in the trend - the Chinese insurers like <a href="https://www.smartkarma.com/entities/china-life-insurance-co-ltd-9f877d22-7cf7-4b00-b525-cec71139f369" target="_blank" data-smartkarma-citation="entities:5794:1" rel="noopener">China Life (2628 HK)</a> and securities companies like <a href="https://www.smartkarma.com/entities/guolian-securities-co-ltd-h" target="_blank" data-smartkarma-citation="entities:535:1" rel="noopener">Guolian Minsheng Securities H (1456 HK)</a>. </li>
<li>Conservative players, however, may look at the laggards in AH premium contraction like the Chinese banks - <a href="https://www.smartkarma.com/entities/industrial-and-commercial-bank-of-china-limited" target="_blank" data-smartkarma-citation="entities:1119:1" rel="noopener">ICBC (H) (1398 HK)</a> and <a href="https://www.smartkarma.com/entities/china-merchants-bank-co-ltd-3388a037-4214-4997-b45d-520518cfdb57" target="_blank" data-smartkarma-citation="entities:10987:1" rel="noopener">China Merchants Bank H (3968 HK)</a>. </li>
</ul>


The A-H share premium has narrowed by an average of 35pp YTD. Despite the recent A-share recovery, the premium remains depressed relative to the start of the year.
Aggressive players may keep playing the leaders in the trend - the Chinese insurers like China Life (2628 HK) and securities companies like Guolian Minsheng Securities H (1456 HK). 
Conservative players, however, may look at the laggards in AH premium contraction like the Chinese banks - ICBC (H) (1398 HK) and China Merchants Bank H (3968 HK). 


Guangzhou Baiyunshan Pharmaceutical Holdings (874 HK)

Guangzhou Baiyunshan Pharmaceutical Holdings

China International Capital Corporation (3908 HK)

Shanghai Fudan Microelectronics H (1385 HK)

China Strategy: Trading the A-H Premium Stocks